Eli Lilly (LLY)
(Delayed Data from NYSE)
$884.48 USD
-1.46 (-0.16%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $883.15 -1.33 (-0.15%) 8:06 AM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Eli Lilly and Company falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 34,124 | 28,541 | 28,318 | 24,540 | 22,320 |
Cost Of Goods | 7,082 | 6,630 | 7,313 | 5,483 | 4,721 |
Gross Profit | 27,042 | 21,912 | 21,006 | 19,057 | 17,598 |
Selling & Adminstrative & Depr. & Amort Expenses | 20,584 | 14,784 | 14,649 | 12,999 | 12,624 |
Income After Depreciation & Amortization | 6,458 | 7,127 | 6,357 | 6,058 | 4,974 |
Non-Operating Income | 97 | -321 | -202 | 1,172 | 292 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 6,555 | 6,806 | 6,156 | 7,230 | 5,266 |
Income Taxes | 1,314 | 562 | 574 | 1,036 | 628 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5,240 | 6,245 | 5,582 | 6,194 | 4,638 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 3,681 |
Net Income (GAAP) | 5,240 | 6,245 | 5,582 | 6,194 | 8,318 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 7,985 | 8,650 | 7,905 | 7,382 | 6,207 |
Depreciation & Amortization (Cash Flow) | 1,527 | 1,523 | 1,548 | 1,324 | 1,233 |
Income After Depreciation & Amortization | 6,458 | 7,127 | 6,357 | 6,058 | 4,974 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 903.28 | 904.62 | 911.68 | 912.51 | 935.68 |
Diluted EPS Before Non-Recurring Items | 6.32 | 7.94 | 8.16 | 7.93 | 6.04 |
Diluted Net EPS (GAAP) | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 |
Fiscal Year end for Eli Lilly and Company falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 11,302.80 | 8,768.00 | 9,353.40 | 9,498.60 | 8,312.10 |
Cost Of Goods | 2,170.20 | 1,673.50 | 1,788.00 | 1,860.10 | 1,807.40 |
Gross Profit | 9,132.60 | 7,094.50 | 7,565.40 | 7,638.50 | 6,504.70 |
SG&A, R&D, and Dept/Amort Expenses | 4,982.80 | 4,585.50 | 5,109.90 | 7,188.10 | 4,379.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 4,149.80 | 2,509.00 | 2,455.50 | 450.40 | 2,125.70 |
Non-Operating Income | -632.60 | 27.10 | 121.00 | -23.20 | -36.80 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 3,517.20 | 2,536.10 | 2,508.80 | 427.20 | 2,088.90 |
Income Taxes | 550.20 | 293.20 | 319.10 | 484.60 | 325.70 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 2,967.00 | 2,242.90 | 2,189.70 | -57.40 | 1,763.20 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 2,967.00 | 2,242.90 | 2,189.70 | -57.40 | 1,763.20 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 904.25 | 903.80 | 903.98 | 899.84 | 902.70 |
Diluted EPS Before Non-Recurring Items | 3.92 | 2.58 | 2.49 | 0.10 | 2.11 |
Diluted Net EPS (GAAP) | 3.28 | 2.48 | 2.42 | -0.06 | 1.95 |